Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences. Osavampator, formerly known as NBI ...

Neurocrine Biosciences amended its Takeda agreement, gaining exclusive global rights to osavampator for major depressive disorder. Phase 2 data for osavampator showed significant MADRS score ...

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder. The San Diego ...

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX), a neuroscience-focused, biopharmaceutical company, on Tuesday announced the initiation of a Phase 3 registrational study to evaluate the efficacy ...

On Monday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK ) to develop and commercialize osavampator (NBI-1065845/TAK-653).